
 FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
 (Rev. 2-92) PATENT AND TRADEMARK OFFICE

 INFORMATION DISCLOSURE
 STATEMENT BY APPLICANT:

(Use several sheets if necessary)

ATTY. DOCKET NO.: 065435/9009

SERIAL NO.: 10/021,506

APPLICANT: Martin *et al.*

FILING DATE: October 30, 2001

GROUP: Not yet assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
RR	AA	5,032,617	Jul 16, 1991	Lee, <i>et al.</i>	—	—	
RR	AB	5,215,738	Jun 1, 1993	Lee, <i>et al.</i>	—	—	
RR	AC	5,041,653	Aug 20, 1991	Lee, <i>et al.</i>	—	—	
RR	AD	5,874,444	Feb 23, 1999	West	—	—	
RR	AE	3,813,384	May 28, 1974	Vogelsang, <i>et al.</i>	—	—	
RR	AF	5,556,856	Sep 17, 1996	Engel, <i>et al.</i>	—	—	
RR	AG	4,841,047	Jun 20, 1989	Engel, <i>et al.</i>	—	—	
RR	AH	4,665,181	May 12, 1987	Thomas, <i>et al.</i>	—	—	
RR	AI	6,197,785	Mar 6, 2001	Jackson, <i>et al.</i>	—	—	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION YES NO
RR	AJ	WO 91/18591	Dec 12, 1991	PCT	—	—	
RR	AK	WO 00/67734	Nov 16, 2000	PCT	—	—	
RR	AL	EP 0 355 750	Feb 28, 1990	Europe	—	—	
RR	AM	WO 99/11649	Mar 11, 1999	PCT	—	—	
RR	AN	WO 99/11624	Mar 11, 1999	PCT	—	—	
RR	AO	EP 0 590 551	Apr 6, 1994	Europe	—	—	
RR	AP	WO 00/44726	Aug 3, 2000	PCT	—	—	X (claims)
RR	AQ	WO 99/44612	Sep 10, 1999	PCT	—	—	
RR	AR	EP 0 792 643	Sep 3, 1997	Europe	—	—	
RR	AS	WO 96/19225	Jun 27, 1996	PCT	—	—	
RR	AT	WO 99/11645	Mar 11, 1999	PCT	—	—	
RR	AU	WO 01/16137	Mar 8, 2001	PCT	—	—	
RR	AV	WO 99/08680	Feb 25, 1999	PCT	—	—	
RR	AW	WO 94/10151	May 11, 1994	PCT	—	—	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

RR	AX	D'Amours <i>et al.</i> , 1999, <i>Biochem. J.</i> 342: 249-268
RR	AY	d'Adda di Fagagna <i>et al.</i> , 1999, <i>Nature Gen.</i> , 23(1): 76-80
RR	AZ	Althaus, F.R. and Richter, C., 1987, ADP-Ribosylation of Proteins: Enzymology and Biological Significance, Springer-Verlag, Berlin – not being sent

EXAMINER

RR

DATE CONSIDERED

12-16-04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Rev. 2-92) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.: 065435/9009

SERIAL NO.: 10/021,506

APPLICANT: Martin *et al.*

FILING DATE: October 30, 2001

GROUP: Not yet assigned

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT:

(Use several sheets if necessary)

RR	BA	Rhun <i>et al.</i> , 1998, <i>Biochem. Biophys. Res. Commun.</i> , 245: 1-10
RR	BB	Miwa <i>et al.</i> , 1977, <i>Arch. Biochem. Biophys.</i> 181: 313-321
RR	BC	Burzio <i>et al.</i> , 1975, <i>Proc. Soc. Exp. Biol. Med.</i> 149: 933-938
RR	BD	Hirai <i>et al.</i> , 1983, <i>Cancer Res.</i> 43: 3441-3446
RR	BE	Durkacz <i>et al.</i> , 1980, <i>Nature</i> 283: 593-596
RR	BF	Berger, N.A., 1985, <i>Radiation Research</i> , 101: 4-14
RR	BG	Ben-Hur <i>et al.</i> , 1984, <i>British Journal of Cancer</i> , 49 (Suppl. VI): 34-42
RR	BH	Schlicker <i>et al.</i> , 1999, <i>Int. J. Radiat. Biol.</i> , 75: 91-100
RR	BI	Wang <i>et al.</i> , 1995, <i>Genes Dev.</i> , 9: 509-520
RR	BJ	Ménissier de Murcia <i>et al.</i> , 1997, <i>Proc. Natl. Acad. Sci. USA</i> , 94: 7303-7307
RR	BK	Cantoni <i>et al.</i> , 1989, <i>Biochim. Biophys. Acta</i> , 1014: 1-7
RR	BL	Szabo, <i>et al.</i> , 1997, <i>J. Clin. Invest.</i> , 100: 723-735
RR	BM	Cosi <i>et al.</i> , 1994, <i>J. Neurosci. Res.</i> , 39: 38-46
RR	BN	Said <i>et al.</i> , 1996, <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 93: 4688-4692
RR	BO	Liaudet <i>et al.</i> , 2000, <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 97(3): 10203-10208
RR	BP	Gäken <i>et al.</i> , 1996, <i>J. Virology</i> , 70(6): 3992-4000
RR	BQ	Rattan and Clark, 1994, <i>Biochem. Biophys. Res. Comm.</i> , 201 (2): 665-672
RR	BR	Berge <i>et al.</i> , 1977, "Pharmaceutically Acceptable Salts," <i>J. Pharm. Sci.</i> , Vol. 66, pp. 1-19. <u>Protective Groups in Organic Synthesis</u> (T. Green and P. Wuts, Wiley, 1991).
RR	BS	Yamaguchi, <i>et al.</i> , <i>J. Med. Chem.</i> 1993, 36, 4052 - 4060 <u>Remington's Pharmaceutical Sciences</u> , 18th edition, Mack Publishing Company, Easton, Pa., 1990
RR	BT	Skehan, P., <i>et al.</i> , 1990, <i>J. Natl. Cancer Inst.</i> , 82, 1107-1112
RR	BU	Perkins <i>et al.</i> , <i>Cancer Research</i> , 61, 4175-4183 (2001)
RR	BV	Chemical Abstracts 122:204573, 1995,
RR	BW	Chemical Abstracts 104:102050, 1985
RR	BX	Chemical Abstracts 134:65983, 2000.
RR	BY	Chemical Abstracts 132:273943, 1999.
RR	BZ	Yamaguchi, <i>et al.</i> , <i>J. Med. Chem.</i> , 36, 4061-4068 & 4052-4060 (1993)
RR	CA	Banasik, <i>et al.</i> , <i>J. Biol. Chem.</i> , 267, 1569-1575 (1992)
RR	CB	Hall, Wong & Chapman, <i>Anti-Cancer Drugs</i> , Vol. 6 - 1995, pp 147-155 (relates to a Chem Abs)
RR	CC	Bold, G., <i>et al.</i> , <i>J. Med. Chem.</i> , 2000, 43, 2310-2323
RR	CD	UKPO Search Report, 2000.
RR	CE	Martin, N., <i>et al.</i> , Abstract 107, ADPR 2001 13 th International Symposium on ADP-ribosylation


EXAMINER

DATE CONSIDERED

12-16-01

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute of form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (use as many sheets as necessary)		Application Number	10/021,506
		Filing Date	October 30, 2001
		First Name Inventor	Niall Morrison Barr Martin
		Group Art Unit	1624
		Examiner Name	Richard L. Raymond
Sheet 1 of 1	Attorney Docket Number	065435-9009	

U.S. PATENT DOCUMENTS				
Examiner Initials		U.S. Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Country Code	Foreign Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Translation	English Abstract
RR	PCT	WO/00/05219	Zambon Group S.P.A.	3 February 2000		
RR	IT	MI98A001671	Zambon Group S.P.A.	22 April 1999		

Examiner Signature	<i>R. Raymond</i>	Date Considered	12-16-04
--------------------	-------------------	-----------------	----------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 0231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box Alexandria, VA 22313-1450.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Rev. 2-92) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.: 0965435/9009


SERIAL NO.: 10/021,506

APPLICANT: Niall Morrison Barr Martin et al.

FILING DATE: October 30, 2001

CONFIRMATION NO. 8516

GROUP: 1711



U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

TECH CENTER
OCT 2

Q:\CLIENT\065435\9009\B0170511.1

EXAMINER

DATE CONSIDERED

12-16-02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED
OCT 24 2002
TECH CENTER 1600/2900



PTO/SB/08A

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/021,506		
		Filing Date	October 30, 2001		
		First Name Inventor	Niall Morrison Barr Martin		
		Group Art Unit	1624		
Sheet	1	of	1	Examiner Name	
				Attorney Docket Number	065435-9009

U.S. PATENT DOCUMENTS				
Examiner Initials		U.S. Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Country Code	Foreign Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Translation	English Abstract
JP	EP	0 634 404 A1	Rhone Poulenc Agriculture Ltd.	1/18/1995		


Examiner Signature	<i>J.P. Raynal</i>	Date Considered	9-3-01
--------------------	--------------------	-----------------	--------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 0231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box Alexandria, VA 22313-1450.

#7


 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
 PTO/SB/08B

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 49B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
Sheet	1	of	1
		Application Number	10/021,506
		Filing Date	October 30, 2001
		First Named Inventor	Niall Morrison Barr Martin
		Group Art Unit	1711
		Examiner Name	Unknown
		Attorney Docket Number	065435-9009

 RECEIVED
 MAY 21 2003
 TC 1700

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
RR	CG	BOLD et. al., New Anilinophthalazines as Potent and Orally Well Absorbed Inhibitors of the VEGF Receptor Tyrosine Kinases Useful as Antagonists of Tumor-Driven Angiogenesis, J. Med. Chem, 2000, 43, 2310-2323
RR	CH	BOLD et. al., J. Med. Chem., 2000, 43, 3200

 RECEIVED
 MAY 29 2003
 TECH CENTER 1600/2800

Examiner Signature	<i>RR Campbell</i>	Date Considered	9-3-04
--------------------	--------------------	-----------------	--------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

 Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.
 DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ATTY. DOCKET NO.: 0965435/9009

SERIAL NO.: 10/021,506

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT:**

APPLICANT: Niall Morrison Barr Martin et al.

(Use several sheets if necessary)

FILING DATE: October 30, 2001

CONFIRMATION NO. 8516

GROUP: 1711



U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

INITIAL
of record
PTO 1449-02
10-3

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER

DATE CONSIDERED

12-16-02

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



(Use several sheets if necessary)

GROUP: 1711

[illegible][illegible]

TECH CENTER
OCT 2

Q:\CLIENT\065435\9009\B0170511.1

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED
OCT 24 2002
TECH CENTER 1800/2900

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Rev. 2-92) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.: 065435/9009


SERIAL NO.: 10/021,506

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT:APPLICANT: Martin *et al.*

(Use several sheets if necessary)

FILING DATE: October 30, 2001

GROUP: Not yet assigned



U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION YES NO
	CF	WO 98/43477	Oct. 8, 1998	PCT		

of
record
1449
of
6-05-02

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

CG	El Tamaty, <i>et al.</i> , "Synthesis and biological activity of some 4-benzyl-1(2H)-phthalazinone derivatives," <i>Chemical Abstracts</i> , 300924j, v. 125, No. 23 (1996)
CH	El-Tamaty, <i>et al.</i> , "Synthesis and biological activity of some 4-benzyl-1(2H)-phthalazinone derivatives," <i>Indian J. Chemistry</i> , v. 35B, pp. 1067-1072 (Oct. 1996)
CI	Shimizu, T., <i>et al.</i> , "Inhibitory effects of Azelastine and Tranilast on leukotriene C ₄ generation by rat colonic mucosa," <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 53, 355-358(1995)

of
record
1449
of
6-05-02

Q:\CLIENT\065435\9009\B0143513.1

EXAMINER

DATE CONSIDERED

12-16-04

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

#5

Sheet 1 of 1

FORM PTO-1449
(Rev. 2-92)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.: 065435/9009

SERIAL NO.: 10/021,506

APPLICANT: Martin *et al.*

FILING DATE: October 30, 2002

GROUP: Not yet assigned



INFORMATION DISCLOSURE
STATEMENT BY APPLICANT:

(Use several sheets if necessary)

RECEIVED
NOV 01 2002
TECH CENTER 1680/2800

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE

COPY OF PAPERS
ORIGINALLY FILED

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION YES NO
	CF	WO 98/43477	Oct. 8, 1998	PCT		

RECEIVED
JUN 11 2002
TC 1700

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	CG	El-Tamaty, <i>et al.</i> , "Sy[n]thesis and biological activity of some 4-benzyl-1(2H)-phthalazinone derivatives," <i>Chemical Abstracts</i> , 300924j, v. 125, No. 23 (1996)
	CH	El-Tamaty, <i>et al.</i> , "Synthesis and biological activity of some 4-benzyl-1(2H)-phthalazinone derivatives," <i>Indian J. Chemistry</i> , v. 35B, pp. 1067-1072 (Oct. 1996)
	CI	Shimizu, T., <i>et al.</i> , "Inhibitory effects of Azelastine and Tranilast on leukotriene C ₄ generation by rat colonic mucosa," <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 53, 355-358(1995).

Q:\CLIENT\065435\9009\B0143513.1

EXAMINER

DATE CONSIDERED

11-21-03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.